{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:37:40Z","timestamp":1789623460341,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jns.2026.125982","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:22:34Z","timestamp":1778196154000},"page":"125982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Chimeric antigen receptor T-cell therapy in neurological disorders: Emerging applications, evidence, and challenges"],"prefix":"10.1016","volume":"487","author":[{"given":"Jin Jun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2026.125982_bb0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125982_bb0010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.jns.2026.125982_bb0015","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.125982_bb0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6382","key":"10.1016\/j.jns.2026.125982_bb0025","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jns.2026.125982_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jns.2026.125982_bb0035","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jns.2026.125982_bb0040","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"Muller","year":"2026","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.jns.2026.125982_bb0045","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jns.2026.125982_bb0050","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.125982_bb0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.27029","article-title":"The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases","volume":"96","author":"Brittain","year":"2024","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2026.125982_bb0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jns.2026.125982_bb0065","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"482","key":"10.1016\/j.jns.2026.125982_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125982_bb0075","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2026.125982_bb0080","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125982_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jns.2026.125982_bb0090","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2024-205103","article-title":"CD19-directed CAR T cell therapy in 4 patients with refractory multiple sclerosis","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jns.2026.125982_bb0095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2026.125982_bb0100","doi-asserted-by":"crossref","first-page":"103621","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jns.2026.125982_bb0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2026.125982_bb0115","first-page":"60","article-title":"Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.jns.2026.125982_bb0120","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jns.2026.125982_bb0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.jns.2026.125982_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jns.2026.125982_bb0140","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jns.2026.125982_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.22230","article-title":"A gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Magliozzi","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2026.125982_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2026.125982_bb0155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.jns.2026.125982_bb0160","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2026.125982_bb0165","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain"},{"issue":"26","key":"10.1016\/j.jns.2026.125982_bb0170","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2026.125982_bb0175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/WCO.0000000000000233","article-title":"Paranodal and other autoantibodies in chronic inflammatory neuropathies","volume":"28","author":"Querol","year":"2015","journal-title":"Curr. Opin. Neurol."},{"issue":"9869","key":"10.1016\/j.jns.2026.125982_bb0180","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2026.125982_bb0185","series-title":"Hematology 2014, the American Society of Hematology Education Program Book","first-page":"567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016"},{"issue":"8","key":"10.1016\/j.jns.2026.125982_bb0190","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.jns.2026.125982_bb0195","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jns.2026.125982_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell\u2013associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.jns.2026.125982_bb0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jns.2026.125982_bb0215","doi-asserted-by":"crossref","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ. Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy. Blood, The Journal of the American Society of Hematology. 2018;131(1):121\u2013130.","DOI":"10.1182\/blood-2017-07-793760"},{"issue":"5","key":"10.1016\/j.jns.2026.125982_bb0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.jns.2026.125982_bb0225","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jns.2026.125982_bb0230","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.125982_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12974-025-03668-0","article-title":"CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders","volume":"23","author":"Samadzadeh","year":"2025","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.jns.2026.125982_bb0240","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41591-025-04191-8","article-title":"Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases","volume":"32","author":"Becilli","year":"2026","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125982_bb0245","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00262-020-02829-9","article-title":"Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL","volume":"70","author":"Tan","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jns.2026.125982_bb0255","doi-asserted-by":"crossref","unstructured":"Ling W, XU C, Tang J, Lu S, Wu C. Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives. Front. Pediatr. 2026;14:1740566.","DOI":"10.3389\/fped.2026.1740566"},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.jns.2026.125982_bb0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.125982_bb0270","first-page":"760","article-title":"Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"48","author":"Masson-Roy","year":"2021","journal-title":"Can. J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.jns.2026.125982_bb0275","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.125982_bb0280","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/ene.15857","article-title":"Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"30","author":"Zheng","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.125982_bb0285","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0290","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4274\/balkanmedj.galenos.2023.2022-10-56","article-title":"Risk of secondary malignancies in hematopoietic stem cell transplantation recipients: a nationwide population-based study in Taiwan","volume":"40","author":"Liu","year":"2023","journal-title":"Balkan Med. J."},{"issue":"1","key":"10.1016\/j.jns.2026.125982_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5144\/1658-3876.2012.1","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"5","author":"Majhail","year":"2012","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0300","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","article-title":"Solid cancers after bone marrow transplantation","volume":"19","author":"Bhatia","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2026.125982_bb0305","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:15:02Z","timestamp":1787058902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26002649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"alternative-id":["S0022510X26002649"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125982","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cell therapy in neurological disorders: Emerging applications, evidence, and challenges","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125982"}}